Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 16Neoplasms 14Prostatic Neoplasms 10Hematologic Neoplasms 9Colorectal Neoplasms 8Lung Neoplasms 5Hematopoietic and Lymphatic System Neoplasm 5Squamous Cell Carcinoma of Head and Neck 4Anatomic Stage I Breast Cancer AJCC v8 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Malignant Solid Neoplasm 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Parotid Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Head and Neck Carcinoma 2Glioma 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2COVID-19 2

Interventions

Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Progressive Metastatic Castrate Resistant Prostate Cancer × Standard of Care × 90 days × Clear all
NCT07206056 2026-06-03

TulmiSTAR-01

Novartis

Phase 1/2 Recruiting
188 enrolled
Genitourinary

Progressive Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡